RecruitingEarly Phase 1NCT05700617

Cardiac Power Output in Cardiogenic Shock Patients

Myocardial Reserve in Advanced Heart Failure Patients


Sponsor

University of Chicago

Enrollment

5 participants

Start Date

Jul 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of this study is to determine whether differences in myocardial reserve predict clinical outcomes for heart failure patients.


Eligibility

Min Age: 18 Years

Inclusion Criteria9

  • LVEF ≤ 40%
  • Referred for RHC for:
  • Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR
  • Accurate assessment of invasive hemodynamics due to worsening clinical status, OR
  • Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR
  • Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI
  • Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2
  • Age ≥ 18 years-old
  • Intent for admission based on RHC data

Exclusion Criteria5

  • eGFR \< 30 ml/min/1.73 m2
  • Severe, non-revascularized coronary artery disease
  • Concurrent acute coronary syndrome
  • Age \< 18 years-old
  • History of significant ventricular arrhythmia without an ICD

Interventions

DRUG1:1 Randomization to receive milrinone

Randomized to receive either inotropic agent: milrinone or no agent


Locations(1)

The University of Chicago

Chicago, Illinois, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05700617


Related Trials